Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nxera Pharma Company Ltd (PK) SOLTF

Healthcare Biotechnology
Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The... see more

Current News (PINL:SOLTF)

Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021

PR Newswire August 12, 2021

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

PR Newswire July 6, 2021

Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials

PR Newswire May 19, 2021

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

PR Newswire February 1, 2021

Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target

PR Newswire January 12, 2021

Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs

PR Newswire January 5, 2021

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

PR Newswire December 22, 2020

Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System

PR Newswire December 20, 2020

Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

PR Newswire December 1, 2020
View More News ››

Opinion & Analysis (PINL:SOLTF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:SOLTF)

Be the first to post on this bullboard.

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. engages in the acquisition and exploration of mineral properties in Chile and Argentina. The company ...
View More »

Podcasts